Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06298409 · ClinicalTrials.gov registry record · Phase 1
Evaluating the Effect Of Rifaximin on the Gut Microbiota and Metabolome in SIBO Using CapScan®
A Phase 1 study of Small Intestinal Bacterial Overgrowth, sponsored by Envivo Bio.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 34
- Enrollment target
- 1
- Study location
NCT06298409: Recruiting Phase 1 study of Small Intestinal Bacterial Overgrowth, sponsored by Envivo Bio.
NCT06298409 is a Phase 1 study of Small Intestinal Bacterial Overgrowth that is actively recruiting participants, run by Envivo Bio. The registered enrollment target is 34 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (43% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06298409, a Phase 1 study of Small Intestinal Bacterial Overgrowth, is actively recruiting participants, sponsored by Envivo Bio.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 34 participants
- Enrollment target
- 1
- Study location
Study Summary
We will sample intestinal microbiota using a microbiome sampling capsule in patients with Small Intestinal Bacterial Overgrowth (SIBO)
Primary Outcome
\> 75% of the retrieved CapScan devices to provide at least 3 million metagenomic DNA sequencing reads of gut microbes from the intestinal tract, and at least 900 annotated gut metabolites.
Conditions Studied
Interventions
- DEVICE CapScan collection capsule
Study Locations (1)
California
- Silicon Valley Gastroenterology - Mountain View
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2024-02-15 |
| Est. Completion | 2026-02-28 |
| Phase | Phase 1 |
What NCT06298409 shows while recruiting
NCT06298409 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 34 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (43% lower).
The record links to 1 condition, with Small Intestinal Bacterial Overgrowth appearing as the primary indexed condition, and to 1 intervention - of which CapScan collection capsule is the first listed.
NCT06298409 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT06298409 about?
NCT06298409 is a clinical study titled "Evaluating the Effect Of Rifaximin on the Gut Microbiota and Metabolome in SIBO Using CapScan®". We will sample intestinal microbiota using a microbiome sampling capsule in patients with Small Intestinal Bacterial Overgrowth (SIBO)
What is the current status of trial NCT06298409?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 34 participants. The study started on 2024-02-15. Estimated completion is 2026-02-28.
What conditions does trial NCT06298409 study?
This clinical trial studies the following conditions: Small Intestinal Bacterial Overgrowth.
What interventions are being tested in trial NCT06298409?
The interventions under investigation include: CapScan collection capsule (DEVICE).
Who is sponsoring clinical trial NCT06298409?
This trial is sponsored by Envivo Bio, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06298409 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Small Intestinal Bacterial Overgrowth
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06298409's enrollment target sits among peer trials
34 1274th of 2000 higher than 721 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02897063 · 34 participants · Phase 1
Effects of Midodrine and Droxidopa on Splanchnic Capacitance in Autonomic Failure
- NCT03906617 · 34 participants · Phase 4
Bupivacaine/Epinephrine +Dexamethasone vs. Liposomal Bupivacaine
- NCT03992378 · 34 participants · NA
Neuromodulation to Regulate Inflammation and Autonomic Imbalance in Sepsis
- NCT04047849 · 34 participants · Phase 4
Latency Antibiotics in Previable PPROM, 18 0/7- 22 6/7 WGA
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI